Compare Abbott India with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DR. REDDYS LAB - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DR. REDDYS LAB ABBOTT INDIA/
DR. REDDYS LAB
 
P/E (TTM) x 47.0 21.5 218.4% View Chart
P/BV x 13.5 3.2 417.9% View Chart
Dividend Yield % 0.5 0.7 69.9%  

Financials

 ABBOTT INDIA   DR. REDDYS LAB
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
DR. REDDYS LAB
Mar-19
ABBOTT INDIA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6,1102,875 212.5%   
Low Rs3,9961,888 211.7%   
Sales per share (Unadj.) Rs1,552.2930.2 166.9%  
Earnings per share (Unadj.) Rs188.8117.4 160.8%  
Cash flow per share (Unadj.) Rs196.4185.8 105.7%  
Dividends per share (Unadj.) Rs55.0020.00 275.0%  
Dividend yield (eoy) %1.10.8 129.6%  
Book value per share (Unadj.) Rs796.6844.4 94.3%  
Shares outstanding (eoy) m21.25166.07 12.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.32.6 127.2%   
Avg P/E ratio x26.820.3 132.0%  
P/CF ratio (eoy) x25.712.8 200.7%  
Price / Book Value ratio x6.32.8 224.9%  
Dividend payout %29.117.0 171.0%   
Avg Mkt Cap Rs m107,376395,496 27.1%   
No. of employees `0003.322.0 15.1%   
Total wages/salary Rs m3,93733,562 11.7%   
Avg. sales/employee Rs Th9,929.37,032.8 141.2%   
Avg. wages/employee Rs Th1,185.11,527.9 77.6%   
Avg. net profit/employee Rs Th1,207.7887.7 136.0%   
INCOME DATA
Net Sales Rs m32,985154,482 21.4%  
Other income Rs m1,1703,375 34.7%   
Total revenues Rs m34,155157,857 21.6%   
Gross profit Rs m5,24531,782 16.5%  
Depreciation Rs m16211,348 1.4%   
Interest Rs m38889 4.3%   
Profit before tax Rs m6,21522,920 27.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2033,858 57.1%   
Profit after tax Rs m4,01219,500 20.6%  
Gross profit margin %15.920.6 77.3%  
Effective tax rate %35.416.8 210.6%   
Net profit margin %12.212.6 96.4%  
BALANCE SHEET DATA
Current assets Rs m22,655111,101 20.4%   
Current liabilities Rs m6,68158,973 11.3%   
Net working cap to sales %48.433.7 143.5%  
Current ratio x3.41.9 180.0%  
Inventory Days Days6579 81.6%  
Debtors Days Days2994 30.9%  
Net fixed assets Rs m835101,245 0.8%   
Share capital Rs m213830 25.6%   
"Free" reserves Rs m16,715139,406 12.0%   
Net worth Rs m16,928140,236 12.1%   
Long term debt Rs m022,000 0.0%   
Total assets Rs m24,162224,656 10.8%  
Interest coverage x163.726.8 611.2%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.40.7 198.5%   
Return on assets %16.89.1 184.7%  
Return on equity %23.713.9 170.5%  
Return on capital %36.914.9 247.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36988,673 0.4%   
Fx outflow Rs m3,80719,104 19.9%   
Net fx Rs m-3,43869,569 -4.9%   
CASH FLOW
From Operations Rs m1,52728,704 5.3%  
From Investments Rs m-2,148-7,727 27.8%  
From Financial Activity Rs m-1,024-21,326 4.8%  
Net Cashflow Rs m-1,646-314 524.1%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.4 146.3%  
FIIs % 0.1 35.3 0.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.1 15.3 111.8%  
Shareholders   18,270 75,885 24.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  AJANTA PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Oct 18, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS